Tesaro makes its case for a clean sweep with niraparib - and shares soar again
We already knew going into the big ESMO meeting that Tesaro’s PARP inhibitor niraparib had demonstrated stellar results for a range of ovarian cancer patients with BRCA mutations. But when investigators stood up to display the results of their pivotal study, a full set of data demonstrated a benefit not only for tumors that were positive for HRD, an important biomarker, but also for HRD-negative tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.